Bicalutamide has not been approved for use as monotherapy.
In one phase II clinical trial with bicalutamide used as a single agent, breast tenderness, breast swelling, and hot flashes were reported in %, %, and % of treated patients, respectively.
Another phase II clinical trial with bicalutamide used as a single agent reported breast pain, and gynecomastia in 76% and 60% of treated patients, respectively. This study also showed generalized pain in 30% of treated patients, hot flashes in 28%, pelvic pain in 26%, and libido decrease and impotence, both at 25%. [ Ref ]
A nonsteroidal antiandrogen ( NSAA ) is an antiandrogen with a nonsteroidal chemical structure .   They are typically selective and full or silent antagonists of the androgen receptor (AR) and act by directly blocking the effects of androgens like testosterone and dihydrotestosterone (DHT).   NSAAs are used in the treatment of androgen-dependent conditions in men and women.  They are the converse of steroidal antiandrogens (SAAs), which are antiandrogens that are steroids and are structurally related to testosterone.